AVRAVRHealthcare · Medical Devices

AVR Stock Forecast: Anteris Technologies Global Corp. Price Predictions for 2026-2027

Last close, 10 Nov 2026
$5.87
−1.18% on the day

The 5 Wall Street analysts covering Anteris Technologies Global Corp. hold a median 12-month price target of $15 — +155.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 9 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$553.9M
Ticker Nerd rank
19/ 100
Median analyst target
$15
Analysts covering
5
Revenue$1.0M+63.3% y/y
Operating income−$31.0M
Net income−$28.8M
Free cash flow−$21.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.8%
1M
−13.3%
YTD
+17.6%
1Y
+48.4%
From 52W high
−44.5%
From 52W low
+73.7%
$3
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AVR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Anteris Technologies Global Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 9 Nov 2026
19/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
73
Momentum
71
Size
50
Accruals
42
Revisions
34
Issuance
19
Volatility
16
Value
12
Quality
9

Growth (73): Sales and profits are climbing, and climbing faster than before.

Quality (9): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

AVR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AVR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15Jan 26Apr 26Jul 26Oct 26AVRHigh $16Median $15Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Low $10Median $15High $16

The green dot is the last close — the median target sits +155.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Oct 2026Cantor FitzgeraldReiteratesOverweight$15
7 Oct 2026BarclaysInitiatesEqual-Weight$10
14 Aug 2026Cantor FitzgeraldReiteratesOverweight$15
14 Aug 2026Cantor FitzgeraldReiteratesOverweight—
15 May 2026BarclaysMaintainsOverweight$17 → $18
15 May 2026BarclaysMaintainsOverweight—
27 Mar 2026Cantor FitzgeraldReiteratesOverweight—
12 Mar 2026Cantor FitzgeraldAssumesOverweight$15
11 Mar 2026Wells FargoInitiatesOverweight—
8 Jan 2025Lake StreetInitiatesBuy—
7 Jan 2025BarclaysInitiatesOverweight—
7 Jan 2025Cantor FitzgeraldInitiatesOverweight—
7 Jan 2025TD CowenInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

AVR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

AVR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 10 Nov 2026, Anteris Technologies Global Corp. returned +48.4% against +11.2% for the S&P 500, dividends included.

AVR vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26AVRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AVR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Anteris Technologies Global Corp. (AVR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.2×

Cheaper than 87% of US stocks

Price / sales
247.3×

Cheaper than 2% of US stocks

Price / book
2.2×

Cheaper than 39% of US stocks

EV / EBITDA
−2.9×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
63.3%

Higher than 88% of US stocks

Earnings growth (YoY)
63.3%

Higher than 78% of US stocks

Gross margin
76.9%

Higher than 89% of US stocks

Operating margin
−3072.1%

Higher than 3% of US stocks

Net margin
70.3%

Higher than 98% of US stocks

Returns & dividend
Return on equity
−74.7%

Higher than 16% of US stocks

Return on assets
−42.5%

Higher than 9% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Anteris Technologies Global Corp. (AVR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Anteris Technologies Global Corp. has a market value of $553.9M and an enterprise value of $301.3M.

  • Revenue in the twelve months to 30 June 2026: $2.2M. The latest quarter grew 63.3% year on year.

  • Net income over the same four quarters: −$102.9M, a −4590.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$88.3M.

  • Shares outstanding: 97.4M.

  • Trailing P/E: −2.2×; forward P/E: −4.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Anteris Technologies Global Corp. employs 174 people — $13K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 10 Nov 2026

Data provided by Twelve Data

Peers

AVR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
AVRAnteris Technologies Global Corp.$553.9M19
SGHTSight Sciences, Inc.$594.6M91
TCMDTactile Systems Technology, Inc.$599.8M97
RCELAVITA Medical, Inc.$529.5M82
SENSSenseonics Holdings, Inc.$511.6M35
DCTHDelcath Systems, Inc.$699.8M98
MASS908 Devices, Inc.$472.2M78

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Anteris Technologies Global Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AVR news & analysis

Anteris Technologies Announces Results for the Third Quarter of 2026

GlobeNewsWire · 10 Nov 2026neutral

Anteris Technologies reported financial results for the quarter ended September 30, 2026, and provided a corporate update. The company said enrollment in its PARADIGM Trial was progressing across active sites in five countries.

Why it matters — AVR watchers may note the reported trial-enrollment progress as part of the company’s quarterly update.

Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

GlobeNewsWire · 1 Nov 2026positive

Anteris reported 30-day outcomes for the medium-size DurAVR THV in 22 patients with severe aortic stenosis and medium aortic annuli in the EMBARK Study. The company said results included single-digit mean gradients, large effective orifice areas, no moderate or severe paravalvular leaks or valve-related mortality, and 100% freedom from moderate or severe prosthesis-patient mismatch.

Why it matters — The reported findings provide clinical and hemodynamic data on the medium-size DurAVR THV from the EMBARK Study.

Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026

GlobeNewsWire · 27 Oct 2026neutral

Anteris announced that Azeem Latib, MD, will present the first 30-day clinical and hemodynamic outcomes for the medium-size DurAVR THV at TCT 2026. The results will cover patients with severe aortic stenosis treated in the ongoing EMBARK study.

Why it matters — The presentation will provide an update on early outcomes for Anteris’s medium-size DurAVR THV in its ongoing clinical study.

Anteris Technologies secures German clearance to expand PARADIGM heart valve trial

Proactive Investors · 20 Oct 2026positive

Anteris Technologies received full German regulatory clearance for its pivotal PARADIGM trial of the DurAVR Transcatheter Heart Valve in patients with severe calcific aortic stenosis. The clearance allows the company to begin recruiting patients and activate German clinical centres.

Why it matters — The clearance enables trial recruitment in Germany and expands PARADIGM’s European footprint.

Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance

GlobeNewsWire · 20 Oct 2026positive

Anteris Technologies Global Corp. received full German regulatory clearance for the DurAVR transcatheter heart valve global pivotal PARADIGM Trial. The clearance allows the company to begin recruiting patients at leading German centers, expanding the trial’s European footprint.

Why it matters — The clearance enables trial recruitment in Germany and marks progress in expanding Anteris’s pivotal trial across Europe.

FAQ

Frequently asked questions about AVR stock

What is the AVR stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Anteris Technologies Global Corp. have a median 12-month price target of $15, with estimates ranging from $10 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AVR stock a buy right now?

Of the 5 analysts covering Anteris Technologies Global Corp., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Anteris Technologies Global Corp. 19 out of 100 across roughly 4,600 US stocks as at 9 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AVR?

As at 9 Nov 2026, Anteris Technologies Global Corp. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (73 of 100).

Will AVR stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +155.5% from the last close, and Ticker Nerd's factor model ranks Anteris Technologies Global Corp. 19 out of 100 as at 9 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AVR stock forecast for 2030?

No analyst covering Anteris Technologies Global Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $16 over the next 12 months.

How has AVR stock performed over the past year?

Anteris Technologies Global Corp. returned +48.4% over the 12 months to 10 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Anteris Technologies Global Corp. do?

Anteris Technologies Global Corp. is a structural heart company focused on designing, developing, and commercializing minimally invasive medical devices for heart valve disease.

What is the latest news on AVR?

The most recent item we track (GlobeNewsWire, 10 Nov 2026): "Anteris Technologies Announces Results for the Third Quarter of 2026". Anteris Technologies reported financial results for the quarter ended September 30, 2026, and provided a corporate update. The company said enrollment in its PARADIGM Trial was progressing across active sites in five countries.

Company

About Anteris Technologies Global Corp.

Anteris Technologies Global Corp. is a structural heart company focused on designing, developing, and commercializing minimally invasive medical devices for heart valve disease. Its portfolio centers on transcatheter aortic valve replacement systems and related technologies intended to restore healthy heart function in patients with aortic stenosis. The company also works on complementary structural heart solutions, including specialized tissue materials and delivery systems that support precise implantation and procedural performance. Anteris Technologies Global Corp. serves the cardiovascular care market, where its products are used by physicians and cardiac specialists in treatment settings that require advanced device-based interventions. With operations spanning multiple regions, the company plays a role in the broader medical technology sector by addressing the needs of patients and clinicians seeking catheter-based alternatives for heart valve repair and replacement.

CEO Mr. Wayne Geoffrey Paterson · 174 employees · Australia · https://anteristech.com